Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present clinical data from its UB-312 program in Parkinson’s disease and preclinical data from its anti-tau program in Alzheimer’s disease at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD 2024), taking place March 5-9, 2024 virtually and in Lisbon, Portugal.

Presentation details are as follows:

Oral Presentation
Title: Evidence of Target Engagement in a Phase 1 Clinical Trial of UB-312 in Parkinson’s Disease
Presenter: Jean-Cosme Dodart, Ph.D., SVP of Research at Vaxxinity
Location: Auditorium VIII
Date & Time: March 6, 2024 at 6:00 PM WET

Poster Presentation
Title: A Randomized, Double Blind, Placebo-Controlled Study with UB-312, an Anti-Alpha-Synuclein Peptide Vaccine in Parkinson’s Disease Patients
Poster Number: P1049 / #720
Authors: Pepijn Eijsvogel, Hui Jing Yu, Philip Kremer, Lauren Fedor, Igor Radanovic, Dario Mirski, Maurits Vissers, Marieke De Kam, Jean-Cosme Dodart, Geert Jan Groeneveld

Poster Presentation
Title: Efficacy of a New Vaccine Targeting Tau in Mouse Models
Poster Number: P0770 / #1617
Authors: Christopher Brown, Louise Kelly, Jeanne Brooks, Matthew Longo, Justin Boyd, Roxana Carare, Jean-Cosme Dodart

About Vaxxinity

Vaxxinity, Inc. is a purpose-driven biotechnology company committed to democratizing healthcare across the globe. The company is pioneering a new class of medicines aimed at disrupting the existing treatment paradigm for chronic disease, increasingly dominated by monoclonal antibodies, which suffer from prohibitive costs and cumbersome administration. The company’s proprietary technology platform has enabled the innovation of novel synthetic peptide immunotherapy candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimer’s disease, Parkinson’s disease, migraine, and hypercholesterolemia. The technology is also implemented as part of a COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a potentially historic, global impact on human health.